Company intelligence / Profile preview

PODO Therapeutics

Jeonbuk, South Korea

Ownership: Private
Development stage: Other

Overview

PODO Therapeutics develops and deploys patient-derived organoid-based platforms to predict sensitivity and response to anticancer and immuno-oncology therapies (e.g., immune checkpoint inhibitors like nivolumab, HER2-targeted therapy such as trastuzumab), and radiation therapy. Their organoid and immune co-culture platform accurately predicts responses, and clinical correlation studies in lung, gastric, rectal, and colon cancer demonstrate concordance with patient outcomes, enabling personalized treatment stratification. The company completed over 50 case studies in 2023-2024 for early clinical validation.

Therapeutic areas: Oncology
Modalities: Organoid-based diagnosticsCompanion diagnostic
Industry: Molecular Diagnostics

Partnerships

Yonsei University Severance Hospital

Beyond the preview

Go deeper on PODO Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PODO Therapeutics.

Explore the full profile